BAFNA PHARMACEUTICALS
|
The Current P/E Ratio of BAFNA PHARMACEUTICALS is 27.71.
| Share Price | ₹113.0 | Mar 30,2026 |
| Market Cap | ₹267.8 Cr | |
| Earnings-TTM | ₹9.7 Cr | TTM-Standalone Results |
| Price/Earnings | 27.71x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of BAFNA PHARMACEUTICALS
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹267.8 Cr] as on Mar 30,2026
(/) Earnings [ ₹9.7 Cr] based on TTM-Standalone Results
(=) P/E Ratio [ 27.71x ]
Thus, for BAFNA PHARMACEUTICALS , the investors are currently willing to pay 27.71 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of BAFNA PHARMACEUTICALS !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of BAFNA PHARMACEUTICALS over the last five years.
Historical PE (Price/Earnings) ratio chart of BAFNA PHARMACEUTICALS
PE Ratio Performance Analysis for BAFNA PHARMACEUTICALS
- BAFNA PHARMACEUTICALS 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 39.60x.
- BAFNA PHARMACEUTICALS 's operated at median p/e ratio of 42.73x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, BAFNA PHARMACEUTICALS 's p/e ratio peaked in Mar2022 at 57.59x.
- BAFNA PHARMACEUTICALS 's p/e ratio hit its five-year low in Mar2023 of 17.24x.
How does BAFNA PHARMACEUTICALS 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| BAFNA PHARMACEUTICALS | 9.67 | 27.71 | 267.8 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11,001.40 | 38.33 | 421,647.0 |
| DIVIS LABORATORIES LTD | 2,479.00 | 63.68 | 157,862.0 |
| CIPLA LTD | 4,544.70 | 21.74 | 98,795.9 |
| TORRENT PHARMACEUTICALS LTD | 2,272.00 | 62.87 | 142,846.0 |
| DR REDDYS LABORATORIES LTD | 5,508.70 | 19.01 | 104,720.0 |
| MANKIND PHARMA LTD | 1,796.65 | 46.09 | 82,807.2 |
| ZYDUS LIFESCIENCES LTD | 4,933.90 | 17.77 | 87,663.1 |
| LUPIN LTD | 4,669.18 | 22.64 | 105,732.0 |
| AUROBINDO PHARMA LTD | 3,513.20 | 21.54 | 75,690.1 |
| ABBOTT INDIA LTD | 1,524.13 | 36.14 | 55,084.7 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs BAFNA PHARMACEUTICALS 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 17.77x |
| Max industry PE | 63.68x |
| Median industry PE | 27.71x |
| Average industry PE | 34.32x |
You may also like the below Video Courses